Table 4.

Risk of progression of IA after HSCT according to the first AFT given after transplantation as secondary prophylaxis

	No. patients	No. patients with progression of IA after allo-HSCT (%)
First AFT given after transplantation*
Azoles (itraconazole/voriconazole)	93 (50/43)	24 (26)
AmB formulations (c-AmB/ABLC/L-AmB)	58 (25/11/22)	19 (33)
Caspofungin	26	7 (27)
No AFT	6	2 (33)
All patients at risk	129†	27 (21)

AmB indicates amphotericin B; and ABLC, AmB lipid complex.

^*Refers to the AFT used from the time of transplantation as first-line secondary prophylaxis or as second/third-line therapy after toxicity from prior therapy, without progression of the IA.

^†Forty-eight (37%) patients received more than 1 drug as first-line prophylaxis, either in combination or sequentially.